JP2019518724A - インターロイキン４誘導１（ｉｌ４ｉ１）の標的化による呼吸器疾患の治療 - Google Patents

インターロイキン４誘導１（ｉｌ４ｉ１）の標的化による呼吸器疾患の治療 Download PDF

Info

Publication number
JP2019518724A
JP2019518724A JP2018555889A JP2018555889A JP2019518724A JP 2019518724 A JP2019518724 A JP 2019518724A JP 2018555889 A JP2018555889 A JP 2018555889A JP 2018555889 A JP2018555889 A JP 2018555889A JP 2019518724 A JP2019518724 A JP 2019518724A
Authority
JP
Japan
Prior art keywords
il4i1
activity
respiratory
infection
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018555889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518724A5 (enExample
Inventor
キャスリーン、エム．サリバン
キャサリン、クリロ
ポール、レッドフォード
ソーレン、バインケ
デイビッド、ミハロビッチ
カレン、ディー．シンプソン
エディス、エム．ヘッセル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2019518724A publication Critical patent/JP2019518724A/ja
Publication of JP2019518724A5 publication Critical patent/JP2019518724A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018555889A 2016-04-26 2017-04-21 インターロイキン４誘導１（ｉｌ４ｉ１）の標的化による呼吸器疾患の治療 Pending JP2019518724A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662327718P 2016-04-26 2016-04-26
US62/327,718 2016-04-26
PCT/US2017/028806 WO2017189353A1 (en) 2016-04-26 2017-04-21 Treating respiratory diseases by targeting interleukin 4 induced 1 (il4i1)

Publications (2)

Publication Number Publication Date
JP2019518724A true JP2019518724A (ja) 2019-07-04
JP2019518724A5 JP2019518724A5 (enExample) 2020-06-11

Family

ID=58664849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555889A Pending JP2019518724A (ja) 2016-04-26 2017-04-21 インターロイキン４誘導１（ｉｌ４ｉ１）の標的化による呼吸器疾患の治療

Country Status (4)

Country Link
US (1) US20190135911A1 (enExample)
EP (1) EP3448413A1 (enExample)
JP (1) JP2019518724A (enExample)
WO (1) WO2017189353A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3721894A1 (en) * 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN115785277B (zh) * 2022-09-09 2023-06-20 上海百英生物科技股份有限公司 一种抗IL4i1纳米抗体的制备及其应用
WO2025231449A1 (en) * 2024-05-02 2025-11-06 Institute For Myeloma & Bone Cancer Research Prediction, diagnosis, and treatment of multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
EP2414520A2 (en) * 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection

Also Published As

Publication number Publication date
EP3448413A1 (en) 2019-03-06
US20190135911A1 (en) 2019-05-09
WO2017189353A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
JP5382692B2 (ja) 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
EP4067377A1 (en) Development and application of therapeutic agents for tslp-related diseases
CN107074951B (zh) 拮抗性抗-ox40l抗体及其使用方法
US20230391886A1 (en) Compositions and methods for muc18 targeting
CN115551895A (zh) 抗ccr8剂
EP3483283B1 (en) Method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
JPWO2012176765A1 (ja) 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
JP2021530511A (ja) 抗ｐｄ−１抗体、投薬量、およびその使用
JP2025516245A (ja) 抗ヒトｉｌ－４ｒａの抗体及びその使用
JP2019518724A (ja) インターロイキン４誘導１（ｉｌ４ｉ１）の標的化による呼吸器疾患の治療
US20240180963A1 (en) Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens
CN117143238A (zh) 抗人cd24抗体及其应用
US20150140008A1 (en) Uses of cxcl17, a novel chemokine marker of human lung and gastrointestinal disease
CN115485392A (zh) 用于鉴别配体阻断性抗体及用于确定抗体效价的方法
CN116751303B (zh) 一种抗鸟苷酸环化酶2c的纳米抗体及其应用
TW201609814A (zh) 新穎之抗ａｄａｍ１７抗體及其用於癌症治療的用途
WO2024082383A1 (zh) 抗人白介素36受体单克隆抗体及其应用
US20250012808A1 (en) Parallel antibody engineering compositions and methods
JP2025160659A (ja) トランスフェリンレセプターを認識する物質の薬効予測マーカー
WO2025168041A1 (zh) 治疗2型炎症性疾病的组合物和方法
WO2025046393A1 (en) Reagents against human endogenous retroviruses to target cancer cells
CN119978128A (zh) 抗pik3ip1的纳米抗体及其应用
CN103958679A (zh) 变异型α-辅肌动蛋白-4的抗体
CN118974094A (zh) 一种抗原结合蛋白及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211130